Achromatopsia: Genetics and Gene Therapy.

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Achromatopsia (ACHM), or total color blindness, is an inherited retinal disorder impacting cone photoreceptors.
• It causes reduced visual acuity, color blindness, photophobia, and nystagmus from birth or early childhood.
• Mutations in cone photoreceptor genes, particularly CNGA3 and CNGB3, account for up to 90% of ACHM cases.

Purpose of the Study:

• To provide an overview of the genetic and molecular basis of Achromatopsia.
• To summarize current gene therapy research and preclinical studies for ACHM.
• To discuss the outlook for clinical applications of gene therapy in treating ACHM.

Main Methods:

• Review of genetic and molecular mechanisms underlying ACHM.
• Analysis of preclinical gene therapy studies in animal models of ACHM.
• Evaluation of ongoing clinical gene therapy trials for ACHM.

Main Results:

• Pathogenic variants in cone photoreceptor genes lead to functional loss and degeneration of cones.
• Preclinical gene therapy studies have demonstrated functional and morphological improvements in ACHM models.
• Multiple gene therapy programs targeting CNGA3 and CNGB3 mutations have progressed to clinical trials.

Conclusions:

• Gene therapy represents a promising therapeutic strategy for Achromatopsia.
• Clinical trials are actively investigating the safety and efficacy of gene therapy for ACHM.
• Further research and clinical development are crucial for establishing authorized therapies for ACHM.